Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers
暂无分享,去创建一个
[1] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.
[2] J. Bender,et al. Phase I Trial , 1983 .
[3] E. Craig,et al. The heat shock response. , 1985, CRC critical reviews in biochemistry.
[4] S Marsoni,et al. The phase II trial. , 1985, Cancer treatment reports.
[5] B. Barlogie,et al. Chemotherapy for resistant and relapsing multiple myeloma , 1989, European journal of haematology. Supplementum.
[6] B. Barlogie,et al. VAD‐based regimens as primary treatment for multiple myeloma , 1990, American journal of hematology.
[7] H. Nawata,et al. High constitutive expression of heat shock protein 90α in human acute leukemia cells , 1992 .
[8] R. Coombes,et al. Clinical and biological significance of HSP89 alpha in human breast cancer , 1992, International journal of cancer.
[9] H. Nawata,et al. High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells. , 1992, Leukemia research.
[10] D R Ciocca,et al. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. , 1993, Journal of the National Cancer Institute.
[11] D. Slamon,et al. Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. DeMaio. The heat-shock response. , 1995 .
[13] P. Rose,et al. Analysis of heat‐shock protein expression in myeloid leukaemia cells by flow cytometry , 1995, British journal of haematology.
[14] R. Ralhan,et al. Differential expression of 70–kDa heat shock‐protein in human oral tumorigenesis , 1995, International journal of cancer.
[15] R. Ralhan,et al. Differential expression of Mr 70,000 heat shock protein in normal, premalignant, and malignant human uterine cervix. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] F. Ritossa. Discovery of the heat shock response. , 1996, Cell stress & chaperones.
[17] M. Quaia,et al. Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. , 1997, European journal of cancer.
[18] R. Morimoto,et al. The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones. , 1997, Essays in biochemistry.
[19] Mike Clarke,et al. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] W. Pratt. The hsp90-based Chaperone System: Involvement in Signal Transduction from a Variety of Hormone and Growth Factor Receptors , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[21] L. Pearl,et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. , 1999, Journal of medicinal chemistry.
[22] Y. Yarden,et al. Sensitivity of Mature ErbB2 to Geldanamycin Is Conferred by Its Kinase Domain and Is Mediated by the Chaperone Protein Hsp90* , 2001, The Journal of Biological Chemistry.
[23] T. Fojo,et al. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy , 2001, Leukemia.
[24] T. Libermann,et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[25] N. Rosen,et al. Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function* , 2002, The Journal of Biological Chemistry.
[26] F. Hartl,et al. Molecular Chaperones in the Cytosol: from Nascent Chain to Folded Protein , 2002, Science.
[27] L. Neckers,et al. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[28] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[29] R. Bataille,et al. Single versus double autologous stem-cell transplantation for multiple myeloma. , 2003, The New England journal of medicine.
[30] L. Neckers,et al. Heat shock protein 90 as a molecular target for cancer therapeutics. , 2003, Cancer cell.
[31] M. Goetz,et al. The Hsp90 chaperone complex as a novel target for cancer therapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] G. Shore,et al. Regulation of apoptosis by endoplasmic reticulum pathways , 2003, Oncogene.
[33] R. Kyle,et al. Drug therapy: Multiple myeloma , 2004 .
[34] P. L. Bergsagel,et al. Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.
[35] Hartmut Goldschmidt,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.
[36] Zhen Zheng,et al. Antiapoptotic and Anti‐inflammatory Mechanisms of Heat‐Shock Protein Protection , 2005, Annals of the New York Academy of Sciences.
[37] P. Richardson,et al. Safety and Activity of KOS-953 in Patients with Relapsed Refractory Multiple Myeloma (MM): Interim Results of a Phase 1 Trial. , 2005 .
[38] S. Lakhani,et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] S. Lindquist,et al. HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.
[40] L. Grochow,et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] T. Libermann,et al. Antimyeloma activity of heat shock protein-90 inhibition. , 2005, Blood.
[42] Jie Ge,et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90 , 2006, Proceedings of the National Academy of Sciences.
[43] A novel, orally active, small molecule Hsp90 inhibitor. , 2006 .
[44] S. Alkan,et al. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma , 2006, Leukemia & lymphoma.
[45] N. Munshi,et al. Activity of New Heat Shock Protein 90 (hsp90) Inhibitor NVP-AUY922 Against Myeloma Cells Sensitive and Resistant to Conventional Agents. , 2007 .
[46] S. Larson,et al. Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer , 2007, Clinical Cancer Research.
[47] Alessandro Corso,et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.
[48] S. Ramalingam,et al. Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers , 2007, Clinical Cancer Research.
[49] H. Müller-Hermelink,et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. , 2007, Blood.
[50] V. Palombella,et al. IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells , 2008, Cancer Chemotherapy and Pharmacology.
[51] N. Munshi,et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[52] J. Boelens,et al. The Endoplasmic Reticulum: A Target for New Anticancer Drugs , 2007 .
[53] N. Munshi,et al. New drugs for myeloma. , 2007, The oncologist.
[54] H. Müller-Hermelink,et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival , 2007 .
[55] G. Morgan,et al. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. , 2007, Blood.
[56] Anthony Boral,et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. , 2007, Blood.
[57] K. Foley,et al. The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. , 2008, Experimental hematology.
[58] 150 POSTER MPC-3100: A non-natural product Hsp90 inhibitor with anti-tumor activity in pre-clinical models , 2008 .
[59] J. Wolchok,et al. Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma , 2008, Clinical Cancer Research.
[60] F. Sarkar,et al. A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer , 2008, Clinical Cancer Research.
[61] L. Fazal,et al. 147 POSTER AT13387, a fragment derived clinical candidate is active in lung and melanoma models , 2008 .
[62] D. Menendez,et al. Understanding the complex crosstalk between p53 and the estrogen receptors at a polymorphic variant of the VEGF receptor Flt-1 promoter , 2008 .
[63] H. Einsele,et al. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma , 2008, Leukemia.
[64] Bin Jiang,et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.
[65] P. Timmermans,et al. 152 POSTER Prevention and treatment of bortezomib-induced peripheral neuropathy by the Hsp90 inhibitor tanespimycin (KOS-953) in the rat , 2008 .
[66] 144 POSTER XL888, a novel, synthetic, orally bioavailable inhibitor of Hsp90 , 2008 .
[67] J. Emery,et al. Regulation of Apoptotic and Inflammatory Cell Signaling in Cerebral Ischemia: The Complex Roles of Heat Shock Protein 70 , 2008, Anesthesiology.
[68] N. Munshi,et al. Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment , 2008, Clinical Cancer Research.
[69] I. Flinn,et al. Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study , 2008 .
[70] J. Sydor,et al. 153 POSTER IPI-493, a potent, orally bioavailable Hsp90 inhibitor of the ansamycin class , 2008 .
[71] Hiroshi Yasui,et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. , 2009, Blood.
[72] C. Erlichman. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90 , 2009, Expert opinion on investigational drugs.
[73] D. Esseltine,et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline , 2009, British journal of haematology.
[74] Xiequn Chen,et al. Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells , 2009, Leukemia & lymphoma.
[75] D. Vesole,et al. Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent , 2009, Expert opinion on investigational drugs.
[76] E. Diamandis,et al. Evaluation of prostate-specific antigen as a novel biomarker of Hsp90 inhibition. , 2009, Clinical biochemistry.
[77] K. Anderson,et al. Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] Philippe Moreau,et al. Autologous hematopoietic stem-cell transplantation for multiple myeloma. , 2009, The New England journal of medicine.
[79] S. Kasibhatla,et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90 , 2009, Molecular Cancer Therapeutics.
[80] John R. Barrett,et al. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress, and induces caspase-dependent cell death in antiestrogen–sensitive and resistant ER+ breast cancer cells , 2010, Autophagy.
[81] K. Bhalla,et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia , 2010, Leukemia.
[82] Hong Zhang,et al. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance , 2009, International journal of cancer.
[83] R. Scannevin,et al. Heat shock protein 90: inhibitors in clinical trials. , 2010, Journal of medicinal chemistry.